BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Indications (1)
Clinical Trials (1)
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Started Apr 2022
1,000 enrolled
Migraine Disorders